Bio-Rad outlines flat to 1% currency-neutral revenue growth for 2025 while expanding ddPCR partnerships

Q3 2025 Management View Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a testament to the discipline and agility ...
Labmate Online

Expanded partnership targets high-sensitivity breast cancer testing

Biodesix, Inc has expanded its long-standing collaboration with Bio-Rad Laboratories to co-develop and clinically validate ...
Hosted on MSN

Bio-Rad raises 2025 life science guidance to flat to 1% growth and expands ddPCR portfolio following Stilla acquisition

Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q2 2025 Norman Schwartz, Chairman & CEO, indicated Bio-Rad delivered solid execution in Q2 2025, with both revenue and operating margin ...
News Medical

From crude lysate to purity with high-precision AAV capsid measurement with Bio-Rad's new ddPCR Kit

insights from industryDr Chelsea PrattBiopharma Segment Marketing ManagerBio-Rad Laboratories In this interview, NewsMedical speaks to Dr Chelsea Pratt about Accurately quantifying AAV capsids ...